Central Nervous System (CNS) Lymphoma Market Overview
Central Nervous System (CNS) Lymphoma or microglioma is a disease in which cancer cells are formed in the lymph tissue of the brain or spinal cord. This is observed primarily in patients with very weak immune systems, patients suffering from immunosuppression, and AIDS patients. Patients who have undergone recent kidney or other organ transplants are also at a high risk of having CNS lymphoma due to their low count of T-Cells or low level of immunity. The major symptoms of this disease include headaches, memory problem, drowsiness, seizures, nausea, vomiting, personality changes, throat infection, body weakness, and sometimes, even hearing loss and double vision. This disease may occur in all age groups; however, it is mostly noticed in people in the 50+ age group. The global central nervous system lymphoma market is estimated to surpass $1,127m by 2023, growing at an estimated CAGR of 6.65% from 2018 to 2023. The North America region is the largest market for CNS lymphoma.
CNS Lymphoma Market Outlook
The report covers the major diagnosis methods including lumber puncture, pathological analysis of cerebrospinal fluid (CSF), brain biopsy sampling, magnetic resonance imaging (MRI), computed topography (CT) scan, stereostatic biopsy, and complete blood count. The market is further categorized by prognosis types, which include Immunocompetent and AIDS. Based on treatment types, the market is segmented into radiation therapy, chemotherapy, steroid therapy, targeted therapy, and others.
CNS Lymphoma Market Growth Drivers
The market is expected to be majorly driven by the rising prevalence of primary CNS lymphoma, increasing awareness regarding the advanced technologies in the market, and rising governmental spending on healthcare. The demand for diagnostic methods is on the surge; thus, propelling the demand for CNS lymphoma treatment across the regions.
CNS Lymphoma Market Challenges
Stringent regulations imposed on drugs by the regulatory bodies coupled with the rising R&D costs pose major challenges for the CNS lymphoma market. Owing to the intake of drug, chances of occurrence of side effects such as fatigue, gastrointestinal complication, graft versus host disease, and late effects of cancer survivors will negatively impact the growth of the market.
CNS Lymphoma Assembly Market Research Scope
The base year of the study is 2017, with forecast done up to 2023. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the CNS lymphoma market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of prognosis and diagnosis in the CNS Lymphoma market, and their treatment methods.
CNS Lymphoma Market Report: Industry Coverage
Prognosis in CNS Lymphoma Market: Immunocompetent and AIDS
Diagnosis in CNS Lymphoma Market: Lumbar Puncture/Pathological Analysis of Cerebrospinal Fluid (CSF), Brain Biopsy Sampling and Stereotactic Biopsy, Magnetic Resonance Imaging (MRI), Computed Topography (CT scan), Complete Blood Count, and Others
Treatment in CNS Lymphoma Market: Radiation Therapy, Chemotherapy, Steroid Therapy, and Others
The CNS lymphoma Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:
- North America: The U.S., Canada, Mexico
- Europe: The U.K., Germany, Italy, France, Spain, Rest of Europe
- APAC: China, Japan, Australia & New Zealand, South Korea, India, Rest of APAC
- RoW: The Middle East, Africa, South America
CNS Lymphoma Market Key Players Perspective
Some of the key players mentioned in this report are Amgen Inc., Celegene Corp., Cipla Inc., Dr. Reddy’s Laboratories, F. Hoffmann-La Roche Ltd., Fresenius SE & CO. KGAA, Gilead Science, Inc., Johnson & Johnson, Merck & CO., Inc., and Sanofi S.A.
CNS Lymphoma Market Trends
- Increased investments in healthcare, and research and development
- Growing prevalence of primary CNS lymphoma, and increasing awareness about advanced technologies in the market
- Advancements in MRI and CT scan technology coupled with increasing healthcare expenditure are driving the growth of the market.
- Diagnosis methods such as Magnetic Resonance Imaging (MRI) accounted for the major share of the total market in 2017. As per IndustryARC analysis, the chemotherapy segment will generate healthy revenue by 2023.